// App-Quantinova.ai

e16539 : Patterns of metastatic disease progression after treatment with first-line enzalutamide or abiraterone in castration-resistant prostate cancer (CRPC).

Researchers

Presenter

  • Elizabeth K Lee

Principal Investigators

  • Benjamin A. Teply

  • Benjamin Louis Maughan

  • Michael Anthony Carducci

  • Emmanuel S. Antonarakis

  • Samuel R. Denmeade

Medical Centers

  • The Johns Hopkins Hospital, Baltimore, MD

  • The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD

  • The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • N/A

Drug/Treatment

  • Enzalutamide

  • CB-7598

  • Docetaxel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved